Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

Ready for Ron Announces Military & Veterans Initiative

Ready for Ron

Ready for Ron, the only credible independent group working to Draft Florida Governor Ron DeSantis to run for President, announced a new initiative to recruit military, veterans, and families to sign its petition to encourage Ron DeSantis to run in 2024. ‘Veterans Ready for Ron’ led by Captain Bob “Shoebob” Carey, US Navy (Ret), will actively engage veterans, military and family voters, and veterans organization leaders. Carey had previously led the RNC’s highly successful 2016 Veterans programs, and numerous veterans and military engagement campaigns. Governor DeSantis is a U.S. Navy veteran, deploying to Iraq in support of the Navy’s SEALs, receiving a Bronze Star Medal, and as Governor is the Commander in Chief of the 12,000 members of the Florida National Guard. “Supporting Ron DeSantis is an easy decision for those who wore the uniform for our country,” stated Captain Bob “Shoebob” Carey, leader of the Veterans Ready for Ron effort. “His record supporting veterans and those in military service is unmatched.” “America needs Governor Ron DeSantis to run for President in 2024, to rebuild and restore our military and honor the pledges this country made to those military veterans once they leave service. He is a decorated veteran, runs one of the largest National Guard forces in the country, and tries to make up for VA ineptitude by building additional veteran assistance programs within his state of Florida,” Carey continued. As a Member of Congress, then Representative DeSantis was a leader on veterans issues, getting bills passed into law that restored combat wounded veterans’ unjustly reduced severance benefits, made Stolen Valor acts a crime, getting a Washington, DC memorial for veterans of the Global War on Terror, getting the VA to pay for service dogs for disabled veterans, and awarding the Congressional Gold Medal to American Ace fighter pilots. Veterans Ready for Ron is recruiting and deploying prominent veterans to lead a public effort to raise awareness, recruit additional veteran and military family voters, and build the veteran organization leadership support for a DeSantis candidacy. “I am thrilled to be working with Bob on this important initiative,” stated Ready for Ron Chief Political Strategist Ed Rollins. “His record of engaging with patriotic Americans who selflessly served our country is impressive. We are glad he is on the Ready for Ron team and look forward to building a movement together.” Bob Carey was a driving force behind the most successful military and veteran voter engagement campaigns in modern American political history. For the 2014 and 2016 campaigns, Bob Carey was National Director of Military and Veteran Engagement for the Republican National Committee, recruiting 50 full-time veteran staffers nationwide, more than 400 active veteran volunteer leaders, more than 500 members of state and regional military and veteran “Task Forces” to support the Republican National Committee and the Trump election effort, while also identifying 1.8 million voters nationwide in various databases as military and veteran voters. Republicans won the veteran vote by 27 percentage points in 2016, the greatest margin of victory ever. “I’m asking all military and veterans to join me in convincing Governor Ron DeSantis, U.S. Navy combat veteran, to bring to the rest of the country his leadership and understanding of what the military and veterans need from their Commander in Chief,” Carey continued. The declining economy, inflation, crime, and erosion of the American military significantly impact veterans and military families. We need confident, dependable, and proven leadership like only Ron DeSantis can deliver to turn the tide.” Since its launch in late May, Ready for Ron has enlisted tens of thousands of supporters, generated significant media attention, and run hundreds of ads to convince Ron DeSantis to run for President. Ready for Ron has emerged as the only credible independent organization in support of a Ron DeSantis candidacy. Americans are encouraged to sign the petition at readyforron.com to draft Ron DeSantis to run in 2024. ### For more information or to schedule an interview with a Ready for Ron or Vets Ready for Ron spokesperson, contact Dan Rene at 202-329-8357 or dan@readyforron.com. Contact Details Dan Rene +1 202-329-8357 dan@readyforron.com Company Website https://www.readyforron.com/

October 03, 2022 10:00 AM Eastern Daylight Time

EF Hutton Reiterates Buy Rating On HCTI, Second Time in 2022

Healthcare Triangle, Inc.

On September 28, 2022, Healthcare Triangle Inc (NASDAQ: HCTI) received a Buy rating with a price target of $2.00 in an analyst report by EF Hutton. EF Hutton analyst Constantine Davides, CFA, said “We are reiterating our Buy rating on HCTI. We continue to like the risk-reward of shares here, as HCTI continues to scale its proprietary Platform offerings while expanding its Managed Services business.” This is the second Buy rating report released by EF Hutton on HCTI in 2022. On March 14, 2022, Davides initiated coverage with a Buy rating on Healthcare Triangle and a price target of $4.00. Here are the key points from the report: Platform Services We view the continued adoption of HCTI's Platform offerings as a key component of potential share appreciation (multiple expansion) and an improved financial profile (predictable/recurring revenue mix and long-term margin expansion). We believe that HCTI has approximately six Platform customers, up from four at the end of 1Q, and we would expect that total to expand steadily across the next several quarters. We are projecting $4.7 million in Platform revenue in 2022 (10% of revenue), growing to $8 million by 2024 (13% of revenue). Managed Services Along with the focus on Platform, we continue to expect HCTI to focus on the growth of this recurring revenue stream. We note that YTD Managed Services revenue growth has been negatively impacted by a change in the way HCTI reports partner pass-through revenue, which has had an optically negative impact on 2022 GAAP revenue with no impact on gross profit. Cash and cash flow A recent (July 2022) equity financing provided HCTI with $5.8M in net proceeds. Although HCTI has been opportunistically repurchasing its own shares, we would prefer that management allow cash to build on its balance sheet rather than deploy capital more aggressively toward repurchases, given the challenging macro backdrop. Free cash flow (FCF) was positive in 1Q and 2Q and we expect FCF generation to remain sound across the next several quarters. Updating target and initiating 2024 estimates Our target moves to $2.00 from $4.00 (2.3x 2023 revenue) given recent multiple compression in the space (our target multiple goes to 1.5x 2023 revenue) and other model adjustments (projected cash and share count). We are initiating our 2024 revenue estimate of $61.3M (+10%). HCTI recently traded at 0.3x our 2023 revenue estimate. Risks HCTI is capital-constrained and has above-average customer concentration risk; its largest customer generated 39% of 2Q revenue. The company’s CEO and CFO also serve as officers of another publicly traded company, SecureKloud Technologies, Inc., which owns 65% of HCTI’s common equity. HCTI has a relatively small float and is thinly traded. View the original report by EF Hutton here. Analyst Certification I, Constantine Davides, CFA, certify that all of the views expressed in this research report accurately reflect my personal views about the subject security(ies) and subject company(ies). I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed in this research report. Company-Specific Disclosures EF Hutton, division of Benchmark Investments, LLC managed or co-managed a public offering of securities for Healthcare Triangle, Inc during the past 12 months. EF Hutton, division of Benchmark Investments, LLC or its affiliates received compensation from Healthcare Triangle, Inc for investment banking services within the past twelve months, and will seek compensation from the companies mentioned in this report for investment banking services within three months following publication of the research report General Disclosure This report has been produced by EF Hutton, division of Benchmark Investments, LLC and is for informational purposes only. It does not constitute solicitation of the sale or purchase of securities or other investments. The information contained herein is derived from sources that are believed to be reliable. Prices, numbers, and similar data contained herein include past results, estimates, and forecasts, all of which may differ from actual data. These prices, numbers, and similar data may also change without prior notification. This research report does not guarantee future performance, and the information contained herein should be used solely at the discretion and responsibility of the client. Neither EF Hutton nor its affiliates accept any liability or responsibility for any results in connection with the use of such information. This research report does not consider specific financial situations, needs, or investment objectives of any client, and it is not intended to provide tax, legal, or investment advice. Clients are responsible for making final investment decisions and should do so after a careful examination of all documentation delivered prior to execution, explanatory documents pertaining to listed securities, etc., prospectuses, and other relevant documents. EF Hutton and its affiliates may make investment decisions based on this research report. In addition, EF Hutton and its affiliates, as well as employees, may trade in the securities mentioned in this research report, their derivatives, or other securities issued by the same issuing companies in this research report. This research report is distributed by EF Hutton and/or its affiliates. The information contained herein is for client use only.EF Hutton holds the copyright on this research report. Any unauthorized use or transmission of any part of this research report for any reason, whether by digital, mechanical, or any other means, is prohibited. If you have any questions, please contact your sales representative. Additional information is available upon request.Certain company names, product and/or service names that appear in this research report are trademarks or registered trademarks of EF Hutton or other companies mentioned in the report. Copyright 2022 EF HUTTON, division of Benchmark Investments, LLC. Contact Details Healthcare Triangle, Inc. Michael Campana michael.c@healthcaretriangle.com Company Website https://www.healthcaretriangle.com

October 03, 2022 09:28 AM Eastern Daylight Time

Biotech Company Pleased With Results Of Early Testing Demonstrating Vaccine Potential For Multiple Sclerosis

Pasithea Therapeutics Corp.

Learn More about Pasithea Therapeutics by gaining access to the latest research report Vaccines that boost the body’s immune system against foreign proteins are different than those that are an inverse vaccine fighting an autoimmune disease. The latest study from Pasithea Therapeutics Corp. (NASDAQ: KTTA) focuses on the latter. Pasithea is a biotechnology company focused on discovering, researching and developing new and effective treatments for psychiatric and neurological disorders. Pasithea recently announced encouraging preclinical results that support the efficacy of a tolerizing DNA vaccine for multiple sclerosis (MS). Based on its experiments conducted with Hooke Laboratories Inc., Pasithea reported that intramuscular injections of the candidate vaccine (PAS002) delayed the onset of paralysis and reduced peak disease severity. Prophylactic administration also reduced the incidence and severity of relapse in the mouse model. According to the National MS Society, nearly 1 million people are living with MS in the United States, which is more than twice the original estimate. “The results of this study show that this technology has the potential to tolerize GlialCAM, a myelin molecule that has molecular similarity to the Epstein Barr virus (EBV) that triggers MS,” Pasithea Chairman and National Academy of Sciences Professor Lawrence Steinman said. Steinman is a globally recognized authority in MS, and his research led to the development of the drug Tysabri, which is approved to treat patients with MS and Crohn's disease. “Remarkably, the piece of GlialCAM protein shared between EBV and white matter in the brain is also found in the pox viruses, including monkeypox,” Steinman said. “Monkeypox is rarely associated with brain inflammation, and this new technology may prove useful for brain inflammation caused by certain viral infections.” GlialCAM Molecules Mimic Epstein Barr Earlier this year, a study in the leading science journal Nature showed that a molecule called GlialCAM found in the brain’s white matter is attacked in MS. GlialCAM shares a component of its protein structure that mimics an identical component of the Epstein Barr virus Nuclear Antigen-1, which plays a critical role in triggering MS. In Pasithea’s proof of concept study, relapsing paralysis was established in a mouse model of relapsing-remitting experimental autoimmune encephalomyelitis (EAE), the standard animal model of MS. In three groups, a proprietary DNA cassette was engineered to encode GlialCAM and injected to block acute disease and its relapse. Pasithea reported that these DNA molecules were designed to protect against paralytic disease by tolerizing the immune system so it would not attack myelin in the brain and spinal cord. The engineered DNA molecule created tolerance and worked as an inverse vaccine. There are currently 15 vaccines actively under development for Epstein-Barr virus, most in preclinical stages. The vaccine is a recombinant vector vaccine that uses the same technology that AstraZeneca plc (NASDAQ: AZN) and Johnson & Johnson (NYSE: JNJ) used in their COVID-19 vaccines. Moderna Inc. (NASDAQ: MRNA), meanwhile, has started testing the vaccine mRNA-1189 in Phase I studies but does not indicate MS, though the company believes it could potentially assist in prevention. Pasithea’s data showed that the engineered DNA plasmids provide a high level of efficacy in reducing disease severity and incidence of relapse when administered prophylactically in the EAE model, a widely used relapsing-remitting model of MS. "Although early stage, we believe these results demonstrate the promise and validity of our tolerizing approach, which is built on recent data on the biological mechanism linking infection with EBV with the development of MS,” Pasithea CEO Dr. Tiago Reis Marques said. “We have filed a provisional patent application, and we will continue to rapidly pursue the PAS002 drug development program.” The study was conducted at Hooke Laboratories, an independent full-service contract research organization with deep experience in the EAE animal model of MS. At future international conferences, Pasithea plans to present its study data, including histology data and plasma inflammatory markers. The company will also submit complete data for peer-review publication. For more information on Pasithea Therapeutics, visit www.pasithea.com. Pasithea Therapeutics Corporation is a biotechnology company focused on the discovery, research and development of new and effective treatments for central nervous system (CNS) disorders. With an experienced team of experts in the fields of neuroscience and psychopharmacology, Pasithea is developing new molecular entities for the treatment of psychiatric and neurological disorders, including Amyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis (MS). Pasithea addresses the needs of patients currently suffering with mental illness by providing access to IV ketamine infusions both in clinics and in-home settings. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details TraDigital IR- Camille Baptiste camille@tradigitalir.com Company Website https://www.pasithea.com/

October 03, 2022 09:09 AM Eastern Daylight Time

The Administration Announced Ending Hunger, Improving Nutrition and Physical Activity, and Reducing Diet-Related Diseases and Disparities

Academy of Integrative Health and Medicine

Joining initiatives announced by the administration at the White House Conference on Hunger, Nutrition, and Health, the Academy of Integrative Health and Medicine (AIHM) and its partner, the Miraglo Foundation, are committing to pledge nearly $4.5 million for health provider education, joining more than $8 billion pledged by other aligned business entities, civic organizations, academic institutions, and philanthropic leaders to end hunger and to reduce nutrition-related disease by 2030. The two organizations have been in conversation with the White House and are aligning in support of the United States Department of Health and Human Services federal programming and coordination efforts related to food and nutrition insecurity and nutrition-related diseases. Specifically, the White House’s plan to end hunger and reduce nutrition-related disease by 2030, and programming outlined by the federal government around integrating nutrition and health, as well as, empowering all consumers to make and have access to healthy choices. AIHM and the Miraglo Foundation, under the leadership of Mimi Guarneri, MD, FACC, ABOIM, and Founding President of AIHM, have committed to fundraising $4.5 million for 10,000 scholarships in fundamental nutrition education and 60 scholarships for the AIHM integrative health fellowship program for physicians, nurses, and other healthcare providers. The AIHM 1000-hour fellowship program offers an inter-professional and comprehensive understanding of integrative health and medicine, which includes clinical nutrition education. AIHM's leadership and board are also committing in-kind hours supporting this commitment and the White House's new strategies. ''We are fully committed to providing access to programs that improve nutrition and healthy lifestyle education for health care providers, including macro and micro nutrition, physical activity, sleep restoration, connection and community, and resilience," said Tabatha Parker, Executive Director, AIHM. "We believe that healthcare will not transform to a model that focuses on lifestyle solutions for chronic disease without the training of healthcare providers and the education of health to consumers," states Dr. Guarneri, AIHM Founding president. AIHM and the Miraglo Foundation commit to fundraising for scholarships worldwide and providing access to programs that complement conventional medical education for healthcare professionals. The two entities envision more healthcare schools with programs addressing these gaps in education. For more information, or if you'd like to support AIHM and the Miraglo Foundation's commitment, please go to www.aihm.org or www.miraglofoundation.org. About AIHM Founded in 1978, the Academy of Integrative Health and Medicine (AIHM) is the leading interprofessional organization for traditional, complementary, and integrative health practitioners worldwide. In 2021, AIHM merged with the Academic Collaborative of Integrative Health (ACIH). Together, they are working to advance integrative health on a global scale and transform health and wellness through education, leadership, collaboration, research, and advocacy. About Miraglo Foundation The Miraglo Foundation is a California-based 501(c)(3) non-profit public charity founded in 2011 by two pioneering integrative healthcare providers, Mimi Guarneri, MD and Rauni Prittinen King, RN, MIH after years of traveling to impoverished communities around the world. "We found out that the only way to make an impact on people's lives is by training existing healthcare providers in healthy lifestyles and serving underserved communities, locally and globally. The White Houses' plan to end hunger and reduce lifestyle related diseases by 2030 fits with our mission and experience," states Rauni Prittinen King RN, MIH, Miraglo Foundation, President. Contact Details AIHM Caitlin Marinaro +1 858-240-9033 cmarinaro@aihm.org Company Website https://aihm.org

October 03, 2022 06:08 AM Pacific Daylight Time

MedMira provides Progress Update

MedMira Inc.

Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the appointment of Dr. Sam Ratnam as MedMira’s Director of Scientific & Regulatory Affairs and provides an update on its regulatory progress in the U.S. market. U.S. Regulatory Update on COVID-19 Products The recent announced recommendation by the U.S. FDA to IVD manufacturers to apply for the traditional regulatory path 510(k) approval outlines the continuous need for quality COVID-19 rapid test. While the Emergency Use Authorisation (EUA) is continuing, the regulators prepare for the future endemic situation and initiate the standard transition protocol for prevailing diseases. In contrary to the EUA application where manufacturer does not require to meet high quality standard, traditional approval process such as the 510(k) requires full compliance with the FDA Quality System Regulation (21 CFR Part 820). It is the most important mandate for all regulators including FDA and Health Canada to approve the highest quality product to serve the public need. Such requirements may include an existing FDA establishment license and the Medical Device Single Audit Program (MDSAP) certification. MedMira’s product lines REVEALCOVID-19 ® and VYRA™ have the data supporting such an application and can provide additional data if such may be required. At the same time, MedMira’s quality system has been certified for the MDSAP and the Company holds both the FDA and Health Canada establishment license for its North-American based facility. The Company continues with its dual strategy to receive the EUA(s) and the 510(k). This enables MedMira and its distributors to offer the highest regulatory approved products when available to market. While MedMira is in the EUA process, the Company is preparing the 510(k) pre-submission. MedMira will provide further updates on both applications when available. U.S. Regulatory Update on Hepatitis C Product The Company has previously announced the intention of seeking FDA approval for its Point of Care Reveal ® Rapid Hepatitis C (HCV) Antibody Test. According to US Centers for Disease Control and Prevention (CDC), the incidence rate of acute hepatitis C in 2020 has more than doubled since 2013, a 124% increase. MedMira has taken immediate steps and a Q-submission (Q220148) was made to FDA and has received positive feedback. The submitted clinical and non-clinical protocols have been reviewed, and the Company has received clear instructions towards obtaining approval for this greatly demanded product in the USA and other parts of the world. Growth of Scientific and Regulatory Support MedMira has eight regulatory applications pending and is aiming to add three additional regulatory submission in the coming months to our three key markets. Therefore, the management has appointed Dr. Sam Ratnam as Director Scientific & Regulatory Affairs to support MedMira in its growth by introducing more products into the North-American and European markets. Dr. Ratnam brings over 40 years of experience in public health, regulatory affairs and has been the principal in a number of important regulations set forward by the health authorities such as the guidelines on Syphilis, Hepatitis C and HPV. His invaluable expertise and intrinsic knowledge of the regulatory and clinical trial framework in Canada and the United States, will provide the Company even further momentum to push forward on its current and future applications. Trademark REVEALCOVID-19 ® MedMira is delighted to announce the receipt of the United States of America Trademark for its REVEALCOVID-19 brand. The trademark complements the MedMira’s portfolio of trademarked brands and further strengthen its uniqueness. Additional trademarks are currently in the final process which includes VYRA™ (Virus based antigen tests), BYRA™ (Bacteria based antigen/antibody tests) and PYRA™ (Parasite based antigen/antibody tests). About Dr. Sam Ratnam Dr. Sam Ratnam, MSc (Medical Microbiology; Madras), PhD (Medical Microbiology; Delhi), MPH (Johns Hopkins), FCCM (Fellow of Canadian College of Microbiologists), is Clinical Professor at Memorial University, St. John's, and Adjunct Professor, McGill University, Montreal, Canada. He was Director of Public Health Laboratory, Government of Newfoundland, St. John's, and served as Advisor to the National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, and Interim Advisor to the Public Health Laboratory, St. John's. He has served as chair or member of many Canadian federal and provincial advisory committees and working groups and as temporary advisor to the WHO. His research interests are clinical and public health microbiology with focus on STI diagnostics (200 scientific articles and abstracts). Next Updates MedMira will provide further updates on its CE and Health Canada progress in a separate announcement. About MedMira MedMira is a leading developer and manufacturer of Rapid Vertical Flow® diagnostics. The Company’s tests provide hospitals, labs, clinics and individuals with instant disease diagnosis, such as HIV, Syphilis, Hepatitis, and SARS-CoV-2, in just three easy steps. The Company’s tests are sold globally under the REVEAL®, REVEALCOVID-19®, Multiplo® and Miriad® brands. Based on its patented Rapid Vertical Flow® Technology, MedMira’s rapid HIV test is the only one in the world to achieve regulatory approvals in Canada, the United States, China and the European Union. MedMira’s corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada. For more information visit medmira.com. Follow us on Twitter and LinkedIn. This news release contains forward‐looking statements, which involve risk and uncertainties and reflect the Company’s current expectation regarding future events, including statements regarding possible regulatory approval, product launch, future growth, and new business opportunities. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Contact Details MedMira Inc. Markus Meile ir@medmira.com Company Website https://medmira.com

October 03, 2022 07:04 AM Eastern Daylight Time

Understanding Inherited Cancer Risk and Genetic Testing

YourUpdateTV

For certain cancers that disproportionally or exclusively affect women, like breast and ovarian cancer, there is a bias to focus on the mother’s side of the family tree in health conversations. And for many, especially previvors – people living at risk of a particular disease but not yet diagnosed – that seemed like enough. But as research has evolved and our understanding of inherited risk has deepened, it has become clearer that genetic risk on our dad’s side of the family can also increase an individual's breast and ovarian cancer risk. Recently, Cancer Previvor Jen Culton and Board-Certified Physician Assistant, Skyler Jesz, participated in a nationwide satellite media tour to discuss inherited risk from dad’s side of the family and some tips to help you take a proactive approach to your health. A video accompanying this announcement is available at: https://youtu.be/0cFRDhC4JHs A recent survey from Myriad Genetics,, a leader in genetic testing, underscores that dad’s side of the family is often overlooked, and much more: More than a third of women do not feel knowledgeable about their father's side of the family. Only 30% of women are very comfortable speaking with their father about their potential risk of getting breast or ovarian cancer, compared to 57% being very comfortable speaking about it with their mother. This is much lower in comparison to the almost 80% of women who consider themselves knowledgeable about their mother’s family health history. 48-year-old Jen Culton sought genetic testing in 2013 after her older sister’s breast cancer diagnosis to find out if she might be at risk. Results showed that she carries a BRCA1 gene mutation and is at increased risk of developing the disease. The news came as a surprise. Jen knew her mother’s health history and it didn’t include cancer. What she didn’t know then: her father’s family history of cancer; the gene mutation came from him. She used this information to take proactive measures to address her risk. For more information, visit myriad.com/knowyourrisk About Jen Culton: Jen Culton is a 48-year-old living previvor. She is at risk for breast and ovarian cancer and came to learn about it in unexpected and surprising ways. It began with her sister Mickey Marasco. Mickey was diagnosed with breast cancer in 2013. Her doctors recommended she undergo genetic testing, and it was discovered that she carries a BRCA1 gene mutation. While undergoing cancer treatment, Mickey had one request: that all six of her siblings undergo genetic testing as well. The siblings went for testing together, and two of Mickey’s sisters (Jen being one of them) were also found to carry the same BRCA1 mutation. For Jen it came as a surprise. She knew her mother’s side did not have a history of cancer. Later she learned that her father’s side did and the gene mutations actually came from their father’s side of the family. But the family’s story doesn’t end there. Jen has three biological daughters – 26, 19, and 10 – who are now facing a similar reality. Genetic testing confirmed that Jen’s oldest daughter is not BRCA1 positive. Her second daughter, however, inherited the BRCA1 mutation from Jen, as well as an ATM gene mutation from her father. Her chances of developing cancer are extraordinarily higher than that of the average woman, up to 87% for breast cancer. With this knowledge, she’s ready to face what’s next, and is considering what proactive measures she should take for her health – just like her mom and her aunts, also BRCA1 positive who sought out proactive measures to manage their risks, and all three are now thriving. About Skyler Jesz, Board Certified Physician Assistant: Skyler Jesz is an Omaha native. She attended the College of Saint Mary, where she earned a Bachelor of Science in Biology. She moved away from Omaha for the first time to attend the physician assistant program at Des Moines University in Des Moines, Iowa. Upon completion of the program, Skyler began her career in the primary care setting, working in a private family practice just outside of Omaha. After more than four years as a primary care provider, she transitioned to her current OBGYN setting. Skyler loves being part of a medical practice that puts patients first and uses the most up-to-date research and recommendations to provide comprehensive and compassionate care. She has a passion for preventative medicine, including genetics and cancer risk assessment. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

September 29, 2022 03:46 PM Eastern Daylight Time

Video

Freelancer wins US$6.7m task order with NASA and the National Institutes of Health in gene editing

FREELANCER.COM

Freelancer Limited (ASX: FLN, OTCQX: FLNCF), the world’s largest freelancing and crowdsourcing marketplace by number of users and jobs posted, today announced it has won a US$6.7 million task order for NASA and the National Institutes of Health (NIH) Office of the Director (OD) Division of Program Coordination, Planning, and Strategic Initiatives (DPCPSI) Office of Strategic Coordination (OSC). NIH seeks two, three-phased contests to encourage technology development in two areas of strategic significance as part of Phase II of the NIH Somatic Cell Genome Editing (SCGE) program: A highly efficient (e.g. 50%+ editing efficiency) non-viral delivery system capable of crossing the blood brain barrier to deliver genome editing machinery to a majority of target cell types in the central nervous system. A programmable (e.g. 3+ configurations) delivery system to deliver genome editing machinery that can target specific tissues or cell types. Somatic cell genome editing holds great promise in treating various diseases. However, current techniques in genome editing approaches, such as those based on CRISPR-Cas9, pose many challenges that need to be overcome before they can be widely used in the clinic. For example, the delivery of genome editors to clinically relevant cells and tissues and achievement of editing efficiency that is adequate for addressing human diseases. These contests will be administered under the America COMPETES Act and will be launched on Freelancer.com with a total prize purse of US$6,000,000 (GMV). This is the biggest task order to date under NASA’s NOIS2 and to be selected is testimony to the company’s track record of delivery to date under the program. It is expected that FLN will generate approximately US$700,000 in net revenue contribution for this task order. About the NIH SCGE Program The NIH Common Fund’s Somatic Cell Genome Editing (SCGE) program is working to improve the efficacy and specificity of gene editing approaches to help reduce the burden of common and rare diseases caused by genetic changes. SCGE is developing quality tools to perform and assess effective and safe genome editing in non-reproductive (“somatic”) cells of the body. These research tools will be made widely available to the research community to reduce the time and cost required to develop new therapies. About Freelancer Twelve-time Webby award-winning Freelancer.com is the world’s largest freelancing and crowdsourcing marketplace by total number of users and projects posted. More than 60 million registered users have posted over 20 million projects and contests to date in over 2,000 areas as diverse as website development, logo design, marketing, copywriting, astrophysics, aerospace engineering and manufacturing. Freelancer owns Escrow.com, the leading provider of secure online payments and online transaction management for consumers and businesses on the Internet with over US$6 billion in transactions secured. Freelancer also owns Freightlancer & Loadshift, enterprise freight marketplaces with over 550 million kilometres of freight posted since inception. Freelancer Limited is listed on the Australian Securities Exchange under the ticker ASX:FLN and is quoted on OTCQX Best Market under the ticker FLNCF. End Contact Details Freelancer.com Marko Zitko +61 404 574 830 mzitko@freelancer.com Freelancer.com Sebastian Siseles +1 415-801-2271 sebastian@freelancer.com

September 29, 2022 10:30 AM Eastern Daylight Time

Landmark Global Review of the Engineering Response to Covid-19 Calls for Action to Ensure Future Pandemic Resilience

Engineering X

Engineering X review of pandemic preparedness identifies key vulnerabilities Senior leaders endorse the need for comprehensive action by policymakers, business and academic leaders worldwide Systemic barriers—including a lack of collaboration mechanisms, insufficient data and skills, and limited understanding and consideration of the role of engineering—reduced the ability of engineers to deliver timely and effective responses to the COVID-19 pandemic, according to a comprehensive review of the global engineering response, published today by Engineering X. The findings of the global review will today be presented to senior delegates from 30 countries during the annual conference of the International Council of Academies of Engineering and Technological Sciences in Versailles, France. The Global review of the engineering response to COVID-19: lessons learned for preparedness and resilience, produced in partnership with Dalberg Advisors, was conceived by the Engineering X Pandemic Preparedness programme at the height of the COVID-19 pandemic in November 2020 to learn lessons and make recommendations to ensure that a more systemic engineering response is put in place to improve preparedness for future pandemics. Ensuring that datasets and data systems used for decision-making are up-to-date and bias-free, equipping emergency response task forces with more engineering capability, and encouraging the use of open science and data sharing standards are just three of the actions recommended by the review group. Informed by data, case studies and comment from more than 40 countries, the review highlights the breadth of contributions made by engineers and engineering globally in responding to key challenges across sectors, disciplines, geographies, and across pandemic prevention, preparedness, response and recovery. It calls on governments, policy makers, public health actors, academia and funders, along with the engineering community, to identify and close structural gaps in resilience against future pandemics, to invest in skills, training and capacity of engineers all around the world, and to develop robust platforms for collaboration within engineering and between engineering and other disciplines. The review highlights transformational innovations in low resource contexts as well as world-changing advances in medical and communication technologies, the pivotal role of data collection, distribution and management, and the importance of applying a systems lens to complex multifaceted challenges. It identifies six major challenges during COVID-19 where engineers made key contributions: Providing high-quality and timely data in near real-time and in appropriate formats, leveraging big data and mobile data for modelling and contact tracing. Innovating rapidly to provide novel health solutions, in collaboration with scientists and clinicians, such as in the design of PPE, diagnostics, breathing aids, vaccines and digital health tools. Designing products and services for diverse environments and user bases to reduce inequality of access and outcomes, such as customised PPE or wastewater testing and vaccine delivery for low-resource settings. Pivoting existing industrial capacity and building new capacity to ramp up production of essential medical and non-medical products such as alcohol manufacturers making hand sanitisers and expanding local vaccine manufacture. Upgrading and streamlining global supply chains to help delivery of essential medical and non-medical products, such as cold chains and drones for last mile delivery of vaccines. Bolstering and ensuring the resilience of societal systems and infrastructure, such as energy and water supplies, or expanding connectivity and digital solutions for remote education or working. The report identifies key drivers that made engineers especially useful during the COVID-19 response, such as rallying around a shared sense of purpose, which empowered them to take risks and to innovate in unprecedented timeframes. For example, engineers from University College London (UCL) designed a breathing aid prototype in under 100 hours and partnered with Mercedes AMG, who repurposed their Formula 1 factories to produce 1,000 devices a day. The open-source design has been made available to local manufacturers around the world. Professor Peter Guthrie OBE FREng, Chair of the Engineering X Pandemic Preparedness board that commissioned the review, said: “As the COVID-19 virus and its impact continues to evolve, there is a need to reflect on the efficacy of our response to it so far and how things might be handled better in the future. Our hope is that we can use the insights provided by this truly global overview of the engineering response to COVID-19 to better integrate engineering skills and habits of mind into resilience policies and structures all around the world, to improve our recovery from the virus, and to help us on the path to a safer, more prepared and resilient future.” Professor Rebecca Shipley OBE, Director of the UCL Institute of Healthcare Engineering and Co-Lead of the UCL Ventura CPAP breathing device programme, said: “The COVID-19 pandemic has highlighted the pivotal role that engineers play in responding to public health emergencies and resilience planning. There are important lessons that we must learn around understanding the needs of providing healthcare in diverse, global settings and working collaboratively across sectors, listening and building trust. Now is the time for governments and international organisations to act on these lessons.” Sir Richard Feachem KBE FREng, Professor Emeritus of Global Health at the Institute for Global Health Sciences, University of California San Francisco, said: “The COVID-19 pandemic has acted as a reminder that a global emergency requires a global response, and that no single country or discipline can tackle a crisis alone. This report reinforces this message and focuses on the role of engineering in this fight. It calls on the global community to learn lessons and act to improve our future pandemic response—creating better mechanisms for global collaboration and coordination, engaging with stakeholders from across disciplines, and developing the skills needed to prevent, prepare for and respond to pandemics.” End NB This press release and the Executive Summary of the global review are both available in French, Spanish and Arabic here: engineeringx.raeng.org.uk/pandemic-preparedness Notes for Editors Dalberg Advisors (2022). Global review of the engineering response to COVID-19: lessons learned for preparedness and resilience. Engineering X (founded by the Royal Academy of Engineering and Lloyd’s Register Foundation). ISBN: 978-1-909327-56-6 CAETS, the International Council of Academies of Engineering and Technological Sciences, annual conference is being held in Versailles near Paris, France, 26–30 September 2022. Engineering X is an international collaboration, founded by the Royal Academy of Engineering and Lloyd’s Register Foundation, that brings together some of the world’s leading problem-solvers to address the great challenges of our age. Our global network of expert engineers, academics and business leaders is working to share best practice, explore new technologies, educate and train the next generation of engineers, build capacity, improve safety and deliver impact. The Engineering X Pandemic Preparedness Programme, led by the Royal Academy of Engineering, is supporting the UK and global engineering community to learn from the COVID-19 pandemic through global sharing of lessons on disruptive solutions and best practice approaches in the prevention, preparedness, response and recovery from pandemics. The Royal Academy of Engineering is harnessing the power of engineering to build a sustainable society and an inclusive economy that works for everyone. In collaboration with our Fellows and partners, we’re growing talent and developing skills for the future, driving innovation and building global partnerships, and influencing policy and engaging the public. Together we’re working to tackle the greatest challenges of our age. The Academy, working with our partners in the National Engineering Policy Centre (NEPC), provided advice to government on a range of areas during the COVID-19 pandemic. Contact Details Royal Academy of Engineering Pippa Cox +44 20 7766 0745 Pippa.Cox@raeng.org.uk Company Website https://engineeringx.raeng.org.uk/

September 29, 2022 05:00 AM Eastern Daylight Time

NYC Health + Hospitals Put Healthier Plant-Based Meals Front and Center

Better Food Foundation

Today at the White House Conference on Hunger, Health, and Nutrition, NYC Health + Hospitals unveiled plans to make healthier, plant-based meals the default for all hospitals in New York City. For years, medical associations like the American Institutes of Cancer have recommended whole food, plant-based diets because they significantly reduce the risk of cardiovascular diseases, Type 2 diabetes, and certain cancers, but our healthcare system has been slow to adopt these recommendations as best practices. Today’s announcement puts NYC Health + Hospitals at the forefront of a growing trend in healthcare to acknowledge the central role that food and nutrition plays in the lifestyle-related diseases that plague tens of thousands of New Yorkers. A team from Greener by Default, an initiative of the Better Food Foundation, worked closely with hospital administrators to facilitate the transition. Greener by Default flips the script by centering plant-based foods by default while giving diners the choice to opt into meat centered options. This strategy aligns with the global health community’s dietary recommendations and allows institutions to spotlight healthier food choices, meet institutional carbon reduction goals, and offer more culturally inclusive meals. “Ninety-five percent of patients in the pilot program responded positively to NYC Health + Hospitals’ incredible new menus that reflect New York’s rich cultural diversity,” said Katie Cantrell, Co-Director of Greener by Default. “These menus are a welcome shift from typical hospital foods that Americans famously dread. Meals like sancocho, a zesty burrito bowl with jicama slaw, and Southern black-eyed peas with plant-based cornbread aren’t just healthier, they’re tastier too.” More Sustainable Our food system accounts for one-third of all global greenhouse gas emissions. Studies have shown that adopting plant-forward diets is necessary to meet the Paris Climate Agreement, as the carbon footprint of plant-based meals is on average half that of animal-based meals. NYC Health + Hospitals serves approximately 4 million meals annually, so offering the default veg menu for lunch and dinner is expected to transition 600,000-800,000 meals from meat to plant-based each year. More Inclusive With nearly 70% of Americans trying to eat more plant-based protein, plant-based defaults are a simple way to meet this growing demand. These menus are more inclusive of diverse diets practiced by Americans for cultural, health, or ethical reasons: 30-50 million Americans are lactose intolerant, many religions encourage vegetarianism or restrict consumption of certain animal products, and a growing number of people are embracing “flexitarianism.” Greener by Default Greener by Default, an initiative of the Better Food Foundation, applies behavioral economics research to food policy, empowering institutions to serve inclusive, sustainable plant-forward food. Visit www.GreenerByDefault.com for free downloadable resources and to schedule a free consultation for your hospital, university, corporation, or anywhere else that meals are served. ### Contact Details Katie Cantrell +1 323-828-7040 Katie@BetterFoodFoundation.org

September 28, 2022 03:17 PM Eastern Daylight Time

Image

1 ... 206 207 208 209 210 ... 310